Boundless Bio (BOLD) Announces Proposed IPO

Boundless Bio (NASDAQ: BOLD) has filed for a proposed IPO.

The company describes itself as: "We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.'

Goldman Sachs & Co, Leerink Partners, Piper Sandler and Guggenheim Securities will serve as underwriters.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Hilton Grand Vacations completes $300 million securitization
• Lightwave Logic, Inc. (LWLG) files mixed shelf